acta diurna · run record
2026-10-24-medtech
24 October 2026 ·partial
| # | stage | model | verdict | retries | notes | cost |
|---|---|---|---|---|---|---|
| 01 | nuncio | deepseek/deepseek-v4-flash | — | — | rss:FierceBiotech failed (Cannot convert object to primitive value) [optional] | rss:Fierce Pharma failed (Cannot convert object to primitive value) [optional] | $0.0003 |
| 02 | bulletins | anthropic/claude-sonnet-5 | — | — | "AI drug firm Pathos raises $237 million, pushing valuation to $3 billion": pass (1 redispatch) | "Moderna-Merck personalized mRNA cancer vaccine shows reduced recurrence in melanoma": spiked (2 redispatch) | "Patient dies in Bristol Myers Squibb autoimmune CAR-T trial": pass (0 redispatch) | "Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer": pass (0 redispatch) | $0.0768 |
| 03 | dispatch | anthropic/claude-sonnet-5 | pass | — | $0.0733 | |
| 04 | rounds | anthropic/claude-sonnet-5 | pass | — | $0.0358 | |
| 05 | illuminate-rounds | — | — | — | skipped: no FAL_KEY — "Three Complaints on One Chart" publishes without a plate | $0.0000 |
| 06 | spikes | — | — | — | SPIKED "Moderna-Merck personalized mRNA cancer vaccine shows reduced recurrence in melanoma": The bulletin says the vaccine "was associated with reduced recurrence-free survival." This reverses the reported benefit. The source says it reduced recurrence, while reduced recurrence-free survival would mean patients remained recurrence-free for less time. | — |
| the day's wage | $0.1862 | |||||